



WEDNESDAY, 12th DECEMBER 2018 COMMENCING 10:30 AM

AT THE [COPTHORNE HOTEL CARDIFF](#), COPTHORNE WAY,

CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting** 1/AWMSG/1218

To protect commercial confidentiality the following appraisals will be held in private

5. **Appraisal 1: Full Submission (WPAS)** 2/AWMSG/1218
Dolutegravir/rilpivirine (Juluca[®]) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor
Appendices

The meeting will now open to the public for the committee decisions

6. **Chairman's report (verbal update)**
7. **Appraisal 2: Limited Submission** 3/AWMSG/1218
Brivaracetam (Briviact[®]) as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 to ≤ 15 years of age with epilepsy. Brivaracetam (Briviact[®]) should be restricted to use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines
Appendices
8. **National Prescribing Indicators 2018-2019 : Analysis of Prescribing Data to June 2018** 4/AWMSG/1218
9. **CEPP National Audit: Antipsychotics in Dementia** 5/AWMSG/1218
10. **Medicines identified as Low Priority for funding in NHS Wales** 6/AWMSG/1218
11. **Feedback from AWPAG meeting held 19th September 2018** 7/AWMSG/1218

Date of next meeting – Wednesday, 13th February 2019 in Cardiff